|
[1]
|
Blokhin N, Larionov L, Perevodchikova N, et al.[Clinical experiences with sarcolysin in neoplastic diseases] [J]. Ann N Y Acad Sci, 1958, 68:1128-1132. doi: 10.1111/j.1749-6632.1958.tb42675.x |
|
[2]
|
McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma[J]. Lancet, 1983, 2:822-824. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=6137651 |
|
[3]
|
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma[J]. N Engl J Med, 1999, 341:1565-1571. doi: 10.1056/NEJM199911183412102 |
|
[4]
|
Orlowski RZ, Eswara JR, Lafond-Walker A, et al.Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor[J]. Cancer Res, 1998, 58:4342-4348. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM9766662 |
|
[5]
|
Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies[J]. J Clin Oncol, 2002, 20:4420-4427. doi: 10.1200/JCO.2002.01.133 |
|
[6]
|
Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells[J]. Cancer Res, 2001, 61:3071-3076. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM11306489 |
|
[7]
|
Kumar SK, Callander NS, Alsina M, et al. Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15:230-269. doi: 10.6004/jnccn.2017.0023 |
|
[8]
|
Moreau P, San Miguel J, Sonneveld P, et al.Multiple myeloma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28:iv52-iv61. http://annonc.oxfordjournals.org/content/21/suppl_5/v155.full |
|
[9]
|
Chng WJ, Dispenzieri A, Chim CS, et al.IMWG consensus on risk stratification in multiple myeloma[J]. Leukemia, 2014, 28:269-277. doi: 10.1038/leu.2013.247 |
|
[10]
|
Dingli D, Ailawadhi S, Bergsagel PL, et al. Therapy for relapsed multiple myeloma:guidelines from the mayo stratification for myeloma and risk-adapted therapy[J]. Mayo Clin Proc, 2017, 92:578-598. doi: 10.1016/j.mayocp.2017.01.003 |
|
[11]
|
Barlogie B, Attal M, Crowley J, et al.Long-term follow-up of autotransplantation trials for multiple myeloma:update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences[J]. J Clin Oncol, 2010, 28:1209-1214. doi: 10.1200/JCO.2009.25.6081 |
|
[12]
|
Porcher R, Lévy V, Fermand JP, et al. Evaluating high dose therapy in multiple myeloma:use of quality-adjusted survival analysis[J]. Qual Life Res, 2002, 11:91-99. doi: 10.1023/A:1015096313594 |
|
[13]
|
Facon T, Mary JY, Harousseau JL, et al. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM)protocol[J]. Blood, 1996, 88:2729. |
|
[14]
|
Child JA, Morgan GJ, Davies FE, et al.High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma[J]. N Engl J Med, 2003, 348:1875-1883. doi: 10.1056/NEJMoa022340 |
|
[15]
|
Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma:final results of phase Ⅲ US intergroup trial S9321[J]. J J Clin Oncol, 2006, 24:929-936. doi: 10.1200/JCO.2005.04.5807 |
|
[16]
|
Rosiñol L, Pérez-Simón JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma[J]. Blood, 2008, 112:3591-3593. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=e3c0b876e7fe028ba2e016172004035e |
|
[17]
|
Lokhorst HM, Segeren CM, Verdonck LF, et al. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma:a prospective evaluation of patients treated in the phase Ⅲ study HOVON 24 MM[J]. J Clin Oncol, 2003, 21:1728-1733. doi: 10.1200/JCO.2003.04.033 |
|
[18]
|
Palumbo A, Bringhen S, Petrucci MT, et al.Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70:results of a randomized controlled trial[J]. Blood, 2004, 104:3052-3057. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM15265788 |
|
[19]
|
Facon T, Mary JY, Hulin C, et al.Melphalan and predni-sone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06):a randomised trial[J]. Lancet, 2007, 370:1209-1218. doi: 10.1016/S0140-6736(07)61537-2 |
|
[20]
|
Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma:a systematic review and meta-analysis of randomized controlled trials[J]. Biol Blood Marrow Transplant, 2007, 13:183-196. doi: 10.1016/j.bbmt.2006.09.010 |
|
[21]
|
Etto LY, Morelli VM, Silva VC, et al. Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients[J]. Clinics (Sao Paulo), 2011, 66:1855-1859. http://europepmc.org/articles/PMC3203955/ |
|
[22]
|
Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma[J]. N Engl J Med, 2017, 376:1311-1320. doi: 10.1056/NEJMoa1611750 |
|
[23]
|
Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma[J]. Blood, 2012, 120:1067-1076. doi: 10.1182/blood-2012-01-405985 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
